Pantop%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions, including Zollinger-Ellison syndrome. ## Adult Dosing * **Erosive Esophagitis (Healing):** 40 mg orally or intravenously once daily for up to 8 weeks. * **Erosive Esophagitis (Maintenance):** 40 mg orally once daily. * **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may need to be increased. Doses up to 240 mg daily have been given. ## Pediatric Dosing * **Erosive Esophagitis (1 to 5 years):** 2.5 mg orally once daily for up to 8 weeks. * **Erosive Esophagitis (5 to 11 years):** 20 mg orally once daily for up to 8 weeks. * **Erosive Esophagitis (12 to 16 years):** 40 mg orally once daily for up to 8 weeks. * Dosing for pathological hypersecretory conditions in pediatrics is not well-established and requires careful consideration and expert consultation. ## Dose Adjustments * **Hepatic Impairment:** Maximum dose of 20 mg orally once daily for patients with severe hepatic impairment. * **Renal Impairment:** No dose adjustment required. ## Contraindications * Known hypersensitivity to pantoprazole or any component of its formulation, or to any substituted benzimidazoles. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness. * **Serious:** Acute interstitial nephritis, *Clostridium difficile*-associated diarrhea, bone fracture (hip, wrist, spine), hypomagnesemia (can be severe and prolonged), vitamin B12 deficiency. ## Key Drug Interactions * **Drugs Dependent on Gastric pH for Absorption:** May decrease absorption of drugs like ketoconazole, itraconazole, posaconazole, iron salts, and vitamin B12. * **Methotrexate:** PPIs may increase levels of methotrexate. Consider a temporary discontinuation of pantoprazole. * **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel, though clinical significance is debated. ## Monitoring * Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, tremors, cardiac arrhythmias). * Monitor for signs and symptoms of *C. difficile*-associated diarrhea. * Consider monitoring vitamin B12 levels with long-term therapy (>3 years). * Monitor bone mineral density in patients at risk for osteoporosis. ## Clinical Pearls * Pantoprazole should be taken at least 1 hour before a meal. * For oral suspension, reconstitute with the provided diluent and shake well. * IV administration should be done over 2 minutes. * Long-term use of PPIs is associated with increased risk of fractures, *C. difficile* infection, and hypomagnesemia. Use the lowest effective dose for the shortest duration necessary. *** *This information is intended for healthcare professionals. Always verify current prescribing information and consult with a pharmacist or physician before making any treatment decisions.*